# ‚öîÔ∏è BOLTZ VS ALPHAFOLD3 STRATEGIC ASSESSMENT

**Date:** October 13, 2025  
**Purpose:** Determine optimal structural validation strategy for future publications

---

## üéØ THE CORE QUESTIONS

1. **Will Boltz deliver what we need for future publications?**
2. **Should we fix Boltz or pivot to AF3?**
3. **What does pLDDT 67.09 actually mean for our science?**

---

## üìä CURRENT BOLTZ PERFORMANCE

### What We Validated (Fast Mode, msa='empty')
- **Runtime:** 16 seconds/protein
- **pLDDT Mean:** 67.09
- **PTM Score:** 0.43
- **Fraction Disordered:** 1.00
- **Mode:** Single-sequence (no MSA)

### What This Means Scientifically

**pLDDT Interpretation:**
- **90-100:** Very high confidence (publication-grade)
- **70-90:** High confidence (generally reliable)
- **50-70:** Low confidence (OK for screening, **NOT** for atomic detail)
- **<50:** Very low confidence (likely wrong)

**Our 67.09 = "Borderline acceptable for relative ranking only"**

**PTM 0.43 = "Poor predicted TM-score"** (want >0.5 for confidence)

**Fraction Disordered 1.00 = "Fully disordered"** (red flag - suggests protein may not fold properly!)

---

## ‚ö†Ô∏è **CRITICAL REALITY CHECK**

### What Boltz Fast-Mode CAN Do:
‚úÖ Rapid screening (16s vs 60+ min)  
‚úÖ Detect gross failures ("wet noodles")  
‚úÖ Relative ranking (A better than B)  
‚úÖ Infrastructure proof-of-concept  

### What Boltz Fast-Mode CANNOT Do:
‚ùå **Publication-grade structural predictions** (pLDDT too low)  
‚ùå **Atomic-detail analysis** (need pLDDT >70)  
‚ùå **Protein-protein interactions** (need full MSA for accuracy)  
‚ùå **gRNA:DNA complexes** (Boltz doesn't natively support nucleic acids well)  
‚ùå **Confident YES/NO on foldability** (fraction_disordered=1.00 is concerning)  

---

## üî¨ WHAT FUTURE PUBLICATIONS REQUIRE

### Week 1 Paper (Metastasis Interception) - **SUFFICIENT**
- ‚úÖ Framework validation (Target Lock, AUROC 0.976)
- ‚úÖ Guide design methodology
- ‚úÖ Infrastructure deployment proof
- ‚ö†Ô∏è Structural validation = "nice to have" (current: adequate for RUO)

### Future Paper #2 (Wet Lab Validation) - **INSUFFICIENT**
- ‚ùå Need **high-confidence structures** (pLDDT >70) for experimental validation
- ‚ùå Need **atomic-detail predictions** for mutagenesis studies
- ‚ùå Need **protein-protein docking** for interaction studies
- ‚ùå Need **gRNA:Cas9:DNA complexes** for guide optimization

### Future Paper #3 (Clinical Translation) - **CRITICALLY INSUFFICIENT**
- ‚ùå Need **publication-grade structures** for regulatory submissions
- ‚ùå Need **full MSA mode** for maximum accuracy
- ‚ùå Need **validated predictions** against crystal structures
- ‚ùå Need **reproducible pipelines** with known accuracy bounds

---

## üéØ BOLTZ FULL-MODE VS AF3 COMPARISON

| Feature | Boltz Fast (Current) | Boltz Full MSA | AlphaFold3 |
|---------|---------------------|----------------|------------|
| **Runtime** | 16s | 60+ min | ~5-10 min |
| **pLDDT** | ~67 | 70-90 | 70-95 |
| **MSA Required** | No | Yes | Yes (or custom) |
| **Protein-Protein** | Supported | Supported | **Best-in-class** |
| **Nucleic Acids** | Limited | Limited | **Native support** |
| **gRNA:DNA** | Poor | Poor | **Designed for this** |
| **Accuracy** | Screening-grade | Good | **State-of-the-art** |
| **Deployment** | ‚úÖ Done | ‚ö†Ô∏è MSA timeout | ‚ùå Weights needed |
| **Publication-Grade** | ‚ùå No | ‚úÖ Yes | ‚úÖ Yes |

---

## ‚öîÔ∏è **STRATEGIC RECOMMENDATION**

### **SHORT TERM (Week 1 Paper):**
‚úÖ **Keep Boltz fast-mode as-is**
- Sufficient for RUO structural validation
- Demonstrates infrastructure capability
- Honest pLDDT reporting (67.09) with limitations documented
- **Verdict:** Ship it with clear RUO disclaimers

### **MEDIUM TERM (Weeks 2-4):**
üîß **Fix Boltz full-MSA mode OR deploy ESMFold as backup**
- **Option A:** Fix Boltz MSA generation (use AF3's custom MSA approach)
  - Pro: Keep existing infrastructure
  - Con: Still won't handle gRNA:DNA complexes well
  - Timeline: 1-2 weeks
  
- **Option B:** Deploy ESMFold (no MSA required, faster than Boltz full)
  - Pro: 1-2 min/protein, pLDDT 70-80, no MSA headaches
  - Con: Monomer-only (no protein-protein or nucleic acids)
  - Timeline: 2-4 hours
  
- **Option C:** Request AF3 weights, build AF3 pipeline
  - Pro: Best-in-class, handles gRNA:DNA natively
  - Con: Weights approval required (~weeks), complex setup
  - Timeline: 2-4 weeks after weight approval

### **LONG TERM (Future Publications):**
üéØ **MUST deploy AlphaFold3 for publication-grade work**
- **Why:** gRNA:DNA complexes, protein-protein interactions, maximum accuracy
- **When:** Before wet lab validation paper (Paper #2)
- **Effort:** 2-4 weeks (weights + integration + validation)
- **Payoff:** State-of-the-art structural predictions for high-impact journals

---

## üìà **VALIDATION REQUIREMENTS BY USE CASE**

### Use Case 1: Target Protein Foldability (Current)
- **Need:** pLDDT >50 (screening), >70 (confident)
- **Boltz Fast:** pLDDT 67 = ‚ö†Ô∏è Borderline
- **Boltz Full:** pLDDT 75-85 = ‚úÖ Good
- **ESMFold:** pLDDT 70-80 = ‚úÖ Good
- **AF3:** pLDDT 80-95 = ‚úÖ Excellent

### Use Case 2: Protein-Protein Interactions
- **Need:** Interface PAE <10, high pLDDT at interface
- **Boltz Fast:** PTM 0.43 = ‚ùå Poor
- **Boltz Full:** PTM 0.6-0.8 = ‚úÖ Good
- **ESMFold:** N/A = ‚ùå Monomer-only
- **AF3:** iPAE <5, PTM >0.8 = ‚úÖ Excellent

### Use Case 3: gRNA:Cas9:DNA Complexes
- **Need:** Nucleic acid modeling, interface prediction
- **Boltz Fast:** N/A = ‚ùå Not designed for this
- **Boltz Full:** Limited = ‚ö†Ô∏è Poor nucleic acid support
- **ESMFold:** N/A = ‚ùå Monomer-only
- **AF3:** Native support = ‚úÖ **ONLY VIABLE OPTION**

### Use Case 4: HDR Template Validation
- **Need:** DNA structure prediction, Cas9:DNA binding
- **Boltz:** ‚ùå Poor
- **ESMFold:** ‚ùå No DNA
- **AF3:** ‚úÖ **REQUIRED**

---

## üéØ **IMMEDIATE ACTION PLAN**

### Week 1 (Current Paper) - **NO CHANGES**
- ‚úÖ Submit with Boltz fast-mode (pLDDT 67.09)
- ‚úÖ Clear RUO disclaimers
- ‚úÖ Document limitations honestly
- **Status:** Complete

### Week 2-3 (Enhancement)
**Option A (Quick Win):** Deploy ESMFold
- **Why:** 1-2 min/protein, pLDDT 70-80, no MSA headaches
- **Effort:** 2-4 hours
- **Use Cases:** Single-protein foldability checks
- **Limitation:** No protein-protein, no DNA

**Option B (Boltz Fix):** Implement custom MSA approach from AF3
- **Why:** Keep existing infrastructure, improve accuracy
- **Effort:** 1-2 weeks
- **Use Cases:** Protein-protein interactions (with caveats)
- **Limitation:** Still poor for gRNA:DNA

### Week 4+ (Production-Grade)
**MUST DO:** Request and deploy AlphaFold3
- **Why:** Future papers (wet lab, clinical) require it
- **Effort:** Request weights NOW (approval takes weeks), then 2-4 weeks integration
- **Use Cases:** Everything (gRNA:DNA, protein-protein, HDR templates)
- **Blocker:** Weights approval

---

## üìä **BOLTZ VALIDATION GAPS**

### What We Know:
‚úÖ Service deploys successfully  
‚úÖ Runs in 16 seconds (fast mode)  
‚úÖ Returns structured output (pLDDT, PTM, disorder)  

### What We DON'T Know:
‚ùå **Accuracy against ground truth** (no crystal structures compared)  
‚ùå **Reliability across protein types** (only 1 smoke test)  
‚ùå **Performance on actual guide designs** (haven't validated real sequences)  
‚ùå **Correlation with wet lab outcomes** (no experimental validation)  

### What We MUST Validate:
1. **Benchmark against known structures** (5-10 proteins with crystal structures)
2. **Test on real guide sequences** (10-20 from our metastasis dataset)
3. **Compare pLDDT to experimental foldability** (if data available)
4. **Assess disorder predictions** (compare to IDPred/IUPred)

---

## ‚öîÔ∏è **COMMANDER'S DECISION MATRIX**

### **For Week 1 Paper:**
**Decision:** ‚úÖ **SHIP WITH BOLTZ FAST-MODE**
- Rationale: Adequate for RUO, demonstrates infrastructure, honest limitations
- Risk: Low (clear disclaimers, not core to validation)

### **For Future Papers:**
**Decision:** üéØ **DEPLOY AF3 (Critical Path)**
- Rationale: gRNA:DNA complexes are NON-NEGOTIABLE for future work
- Timeline: Request weights NOW, deploy in 4-6 weeks
- Backup: ESMFold for simple protein foldability (2-4 hours to deploy)

### **For Boltz Full-MSA:**
**Decision:** ‚è∏Ô∏è **DEFER (Nice-to-Have)**
- Rationale: Effort better spent on AF3 deployment
- Use Case: Backup for protein-protein if AF3 weights delayed
- Priority: Low (ESMFold covers most protein-only use cases)

---

## üöÄ **RECOMMENDED EXECUTION ORDER**

1. **NOW:** Submit Week 1 with Boltz fast-mode (complete)
2. **Week 2:** Deploy ESMFold (4 hours) as immediate protein validation backup
3. **Week 2:** Request AF3 weights (start approval process)
4. **Week 3-4:** Benchmark Boltz fast-mode against known structures (validation)
5. **Week 4-6:** Deploy AF3 (upon weight approval)
6. **Week 6+:** Full validation of AF3 for Paper #2 (wet lab)

---

**VERDICT:** 
- **Boltz Fast-Mode:** ‚úÖ Sufficient for Week 1, NOT for future publications
- **Boltz Full-MSA:** ‚ö†Ô∏è Defer (ESMFold faster, AF3 better)
- **AlphaFold3:** üéØ **CRITICAL for future work - start approval NOW**

---

**Next Action:** Request AF3 weights from Google DeepMind while we finish Week 1 submission


